



Published in final edited form as:

Nat Rev Cancer. 2010 November ; 10(11): 785–794. doi:10.1038/nrc2934.

Engineering the perfect (bacterial) cancer therapy

Neil S. Forbes

Department of Chemical Engineering, University of Massachusetts, Amherst Amherst, MA 01003-9303

Abstract

Bacterial therapies possess many unique mechanisms for treating cancer that are unachievable with standard methods. Bacteria can specifically target tumors, actively penetrate tissue, are easily detected and can controllably induce cytotoxicity. Over that last decade, *Salmonella*, *Clostridium* and other genera have been shown to control tumor growth and promote survival in animal models. In this Innovation article I propose that synthetic biology techniques can be used to solve many of the key challenges associated with bacterial therapies such as toxicity, stability and efficiency; and can be used to tune their beneficial features, allowing the engineering of ‘perfect’ cancer therapies.

Introduction

Bacteria have unique capabilities that make them well-suited as ‘perfect’ anticancer agents. Because their genetics can be easily manipulated, bacteria can be engineered to overcome the limitations that hamper current cancer therapies. Many current treatments, including chemotherapy and radiation, are toxic to normal tissue and cannot completely destroy all cancer cells¹. Three major causes of these problems are incomplete tumor targeting, inadequate tissue penetration and limited toxicity to all cancer cells^{1–3}. These drawbacks prevent effectual treatment and are associated with increased morbidity and mortality.

Using a top-down engineering approach, the ideal cancer therapy can be envisioned: it would be tiny programmable *robot factories* (Figure 1A) that specifically target tumors, are selectively cytotoxic to cancer cells, are self-propelled, are responsive to external signals, can sense the local environment and are externally detectable. Specific targeting would permit the use of more toxic molecules without systemic effects. Self-propulsion would enable penetration into tumor regions that are inaccessible to passive therapies. Responsiveness to external signals would enable precise control of the location and timing of cytotoxicity. Sensing the local environment would permit “smart,” responsive therapies that can make decisions about where and when drugs are administered. Finally, the ability to be externally detected would provide critical information about the state of the tumor, the success of localization and the efficacy of treatment.

Bacteria can be viewed as these perfect robot therapies because they have biological mechanisms to perform all of the ideal functions mentioned above (Figure 1B). Over the last century, many genera of bacteria have been shown to preferentially accumulate in tumors, including *Salmonella*⁴, *Escherichia*⁵, *Clostridium*^{6–7} and *Bifidobacterium*⁸. *Caulobacter*⁹, *Listeria*^{10–11}, *Proteus*¹² and *Streptococcus*¹³ have also been investigated as anticancer agents. For propulsion and sensing, bacteria have flagella that enable tissue penetration¹⁴

and chemotactic receptors that direct chemotaxis towards molecular signals in the tumor microenvironment^{15–16}. For example, the TAR receptor detects aspartate secreted by viable cancer cells and the TRG receptor promotes migration towards ribose in necrotic tissue¹⁶. Selective cytotoxicity can be engineered by transfection with genes for therapeutic molecules, including toxins^{17–19}, cytokines^{20–21}, tumor antigens²² and apoptosis inducing factors^{23–27}. External control can be achieved using gene promoter strategies that respond to small molecules^{17, 28–29} or radiation^{23, 26–27, 30}. Bacteria can also be detected using light^{5, 31–32}, magnetic resonance imaging (MRI)³³ or positron emission tomography (PET)^{34–36}. Finally and most importantly, the ease of genetically manipulating bacteria is the feature that will have the greatest effect on therapy development because it enables precise tuning and limitless functional combinations.

Once fully implemented and tested, the unique capabilities of bacterial therapies will change the way cancer is treated. Manufacture of drugs within tumors would beneficially shift temporal drug concentration profiles compared to intravenous administration (Figure 2). Because bacteria can migrate and accumulate far from vasculature, more of the therapeutic would be present in distal regions for longer periods of time compared to small molecules that only diffuse passively. Intratumoral production would be more toxic to cancer tissue and less toxic to normal tissue. This inversion of drug localization would eliminate tumors from the inside out, and would have the simultaneous effects of increasing efficacy and decreasing damage to normal tissue.

To date many different bacterial strategies have been implemented in animal models (Tables 1 and 2) and some human trials have been carried out (Table 3). Using these strategies, many researchers have observed experimental success, with reduced tumor volume, increased survival and treatment of metastatic disease (Table 1). Success has also been shown treating multiple tumor sites (Table 1); the most notable is pancreatic cancer^{13, 37}, for which new targeted treatments could dramatically improve the poor current prognosis of less than 25% five-year survival. Since the mid 1990's, the number of published bacterial therapy papers has increased with a doubling time of 2.5 years (Figure 1C). This rapid rise has been driven almost entirely by increasing use of *Salmonella* as a delivery vector (Figure 1C). This Innovation article will describe many of the advances that have fuelled this enthusiasm including, specific bacterial targeting of tumors; intratumoral penetration; native bacterial cytotoxicity; expression of anticancer agents; gene triggering strategies; and detection of bacterial therapies.

Bacterial targeting of tumors

One of the major advantages of bacterial therapies for cancer is the ability to specifically target tumors. The mechanisms of bacterial accumulation in tumors differ depending on oxygen tolerance. Obligate anaerobes (e.g. *Clostridium*, and *Bifidobacterium*) cannot survive in oxygen and injected bacterial spores can only germinate in anoxic regions of tumors^{38–39}. Completely deoxygenated tissue is unique to tumors and is not present in most other organs of the body. Obligate anaerobes are therefore highly effective at accumulating in the large hypoxic regions of tumors¹⁴. This absolute specificity was demonstrated early by Malmgren et al. who injected *Clostridium* into tumor-bearing mice and showed that only the mice with tumors died from the infection⁷.

Facultative anaerobes (e.g. *Salmonella* and *Escherichia*) use a more complex set of mechanisms to target tumors. Five interacting mechanisms are thought to control the accumulation of facultative anaerobes in tumors: entrapment of bacteria in the chaotic vasculature of tumors⁴⁰, flooding into tumors following inflammation⁴¹, chemotaxis toward compounds produced by tumors^{15–16}, preferential growth in tumor-specific

microenvironments^{15, 31}, and protection from clearance by the immune system⁴². These mechanisms enable *Salmonella* to accumulate in tumors at ratios greater than 1000:1 compared to organs rich in reticuloendothelial cells (such as the liver and spleen) and even greater in other organs^{40, 43–45}.

When injected systemically, *Salmonella* attach to the walls of tumor vasculature with a low but measurable frequency (~0.035% of bacteria in the blood)⁴⁰. In addition, the number of bacteria that adhere is dependent on blood velocity, suggesting that hemodynamics play an important role in the initial interaction of bacteria with tumors⁴⁰. Similarly, the accumulation of *Salmonella* is associated with an influx of blood into tumors, caused by an immunologically induced rise in the blood concentration of tumor necrosis factor- α (TNF α)⁴¹. This mechanism would be reduced for attenuated *msbB*⁻ strains that elicit much lower (~10%) TNF α levels⁴⁶. The production of TNF α immediately after injection therefore has contradictory effects; it promotes accumulation in tumors but is also the primary cause of bacterial toxicity due to septic shock⁴⁶. This dependence on an immune response to promote targeting could also reduce the utility of repeated dosing with bacteria, which is a limitation that does not affect bacteria delivered as spores⁴⁷.

In *in vitro* tumor models, *Salmonella* identify and penetrate tumors by detecting and chemotaxing towards small molecule gradients of serine, aspartate and ribose^{15–16}. In addition, the growth rate of *Salmonella* is greater in *in vitro* tumors when dying cells are present¹⁵, a phenomenon which is also observed in animal tumor models^{40–41, 46}. The importance of this mechanism for promoting accumulation is supported by the increased tumor specificity of auxotrophic *Salmonella* that require leucine and arginine, which are nutrients derived from dying tumor tissue^{31, 48}.

Because tumors are immune-privileged environments⁴⁹, bacteria can replicate unimpeded by the macrophage and neutrophil clearance mechanisms that normally serve to eliminate them⁵⁰. In this way, the immune system plays a complicated role in bacteriolytic therapy; it provides a mechanism to guide bacterial accumulation, but also impedes dispersion and efficacy. The interaction between bacteria and the immune system also works in reverse; many bacterial therapies sensitize the immune system to induce tumor clearance^{51–52}.

Intratumoral penetration

Intratumoral targeting is an essential characteristic of an optimized cancer therapy (Figure 1). Compared to normal tissue, tumors have chaotic vasculature and large intercapillary distances, impeding delivery of therapeutic molecules^{3, 53}. This reduces therapeutic efficacy by creating cellular regions that have low drug concentrations and reduced nutrient supply^{1, 3}. Low levels of oxygen and glucose create quiescent cells that are unresponsive to chemotherapeutics designed to target rapidly growing cells. Proper intratumoral targeting enables drug delivery directly to these distal, unresponsive cells that are far from tumor vasculature (Figure 2). In this way, the metabolic heterogeneity of tumors is both a blessing and a curse; molecular gradients reduce therapeutic efficacy but also create unique environments that can be targeted.

Motility is the key feature of bacterial therapies that enables intratumoral targeting. Bacteria can actively swim away from vasculature and penetrate deep into tumor tissue (Figure 2). Because bacteria are complex living organisms that can acquire energy from their environment, their transport is not entropically limited. This contrasts to the concentration of passive molecules, which drops with distance from vasculature. Because bacteria are self-propelled, their density can be higher far from the vascular source. It has been shown that bacteria that can disperse throughout tumor tissue have a greater ability to regress tumors¹⁴. *Salmonella* have also been shown to chemotax towards molecules produced by dying tumor

tissue^{15–16}. *Salmonella* contain chemoreceptors that sense small molecules in the local environment. For example, using knockouts, it has been shown that the aspartate receptor initiates chemotaxis towards viable tumor tissue; the serine receptor induces tissue penetration; and the ribose receptor directs migration toward necrotic tissue¹⁶.

In addition to intrinsic motility, the host immune system plays a critical role in preventing bacterial dissemination throughout tumors. Neutrophils have been shown to prevent bacteria from spreading from necrotic into viable tumor tissue⁵⁰. This containment is one possible reason that attenuated *Salmonella* had limited success reducing tumor growth in human trials^{54–56}. Depleting host neutrophils increases tumor bacterial densities and enables spread throughout viable tumor tissue⁵⁰.

Native bacterial cytotoxicity

Many successful experiments have shown that the natural toxicity of bacteria is sufficient to regress tumors (Table 1). Native bacterial cytotoxicity is caused by sensitization of the immune system and competition for nutrients⁴². Although some organisms naturally produce toxins, these are typically removed to prevent pathogenicity¹⁴. Much early work on bacterial therapies relied on natural toxicity because direct genetic modification was not possible. The ability of bacteria to regress tumors has been recognized since the early 1800's⁵⁷. In the time before strict antiseptic technique, tumor regression was occasionally observed following severe bacterial infection⁵⁷. This observation led to the development of Coley's toxin, a bacterial extract that stimulates a general immune response^{57–59}. Because of this early success, this approach persists in many contemporary strategies^{20, 60} that are similarly designed to stimulate immune responses (Table 2). The idea that living bacteria could be anticancer therapeutic agents was first advanced in the middle of the 20th century^{6–7}. The increased availability of antibiotics and the discovery that tumors contain anoxic regions⁶¹ spurred multiple investigations^{6, 62} which showed that *Clostridium*, an obligate anaerobe, could regress tumors in mice (Table 1). There was sufficient enthusiasm to initiate a small clinical trial, and oncolysis was observed in three out of five patients following injection with *C. butyricum*⁶³ (Table 3).

More recently, *Salmonella* has been tested for its anti-cancer properties^{4, 46}, and similar to *Clostridium*, *Salmonella* is naturally cytotoxic and has been shown to regress tumors when administered alone (Table 1A). Immunosenitization is one of the key mechanisms of *Salmonella* cytotoxicity; accumulation of *S. choleraesuis* in tumors induces neutrophil infiltration and antitumor immune responses⁶⁴. When investigated in human trials, *Salmonella* with a modified lipid-A (strain VNP200009) was found to be non-toxic and tumor colonization was observed⁵⁵. In dogs administered VNP200009, colonization was also observed and complete cure was seen in 4 of the 35 animals⁶⁵. There is also potential that *Salmonella* could be delivered orally to reduce toxicity. Following oral administration in mice, *Salmonella* preferentially accumulated in tumors and maintained its anticancer effects⁶⁶ with very low toxicity⁶⁷. Oral delivery may be different in humans, where bacterial escape from the gut into the circulation occurs less often than in mice⁶⁸.

Expression of anticancer agents

Another advantage of bacterial anticancer agents is that they can be genetically modified to increase their effectiveness. Many strategies have been employed (Tables 1, 2) and two major mechanisms have been studied: the direct expression of proteins that have physiological activities against tumors and transfer of eukaryotic expression vectors into infected cancer cells. For both of these mechanisms, three categories of anticancer agents have been investigated: cytotoxic agents that directly kill cancer cells, cytokines that stimulate immune cells to kill cancer cells, and tumor antigens that sensitize the immune

system against cancer cells. Prodrug strategies have been reviewed previously^{69–70} and will not be discussed here.

Cytotoxic agents

Bacterial toxins are the most obvious cytotoxic agents because these genes are native to bacterial physiology. Cytolysin A (ClyA or HlyE) is a bacterial toxin that acts by forming pores in mammalian cell membranes and inducing apoptosis^{18–19}. ClyA is a native bacterial protein that is ready transported to the bacterial surface and secreted without modification^{17–18}. Multiple groups have shown that treating mice with *E. coli* or *S. typhimurium* expressing ClyA reduces tumor growth^{17–19}.

Three of the cytotoxic agents are members of TNF α family: FAS ligand (FASL), TNF-related apoptosis-inducing ligand (TRAIL) and TNF α ^{23–27}. These proteins selectively induce apoptosis via death receptor pathways, which activate caspase-8 and caspase-3, an important apoptotic mediator²³. All three are selectively cytotoxic to cancer cells compared to normal cells^{23–24}. FASL specifically induces apoptosis in cells that possess the FAS receptor²⁴. TNF α and TRAIL have been shown to be cytotoxic towards colon, breast, lung, prostate, renal, ovarian, bladder, glioma and pancreatic tumors^{23, 71}. When systemically administered as protein drugs, all three members of this family have two deficiencies that are overcome by bacterial delivery: hepatotoxicity and a short circulatory half-life^{23, 25–27}. Producing these proteins *in situ* would maintain a higher continual concentration in tumors compared to delivery to the circulatory system (Figure 2), and would reduce the systemic toxicity associated with their administration as small molecules. FASL is also immunologically active: it attracts tumor rejecting granulocytes, induces interleukin (IL23) production by dendritic cells and stimulates proliferation of T cells — three mechanisms that may culminate in specific killing of cancer cells²⁴.

Cytokines

Bacteria can also be engineered to deliver specific cytokines that have anti-tumor effects (Table 2). Cytokines induce immune cells to clear tumors by stimulating multiple mechanisms such as immune cell activation, proliferation and migration. When administered as a small molecule, IL2 activates the cytolytic function of natural killer (NK) and lymphokine-activated killer cells⁷² and promotes lymphocyte proliferation⁷³. Similar to IL2, IL18 (also known as IFN γ -inducing factor) induces T and NK cell proliferation and enhances their production of cytokines⁷⁴. IL18 also suppresses angiogenesis by inhibiting fibroblast growth⁷⁴. CCL21 controls migration of immune cells and may prevent tumor-induced immunosuppression²¹. LIGHT (also known as TNFSF14 and HVEM-L) is a TNF-family cytokine homologous to lymphotoxin that induces dendritic cell (DC) growth²⁰.

IL2 is the most extensively studied bacterially delivered cytokine^{72–73, 75–80}. Reports describing IL2 delivery by *Salmonella* were the first to suggest that this genus could be effectively used as an anticancer agent^{73, 80}. Oral administration of *Salmonella* expressing IL2 has been shown to function prophylactically and prevent tumor formation⁷⁹. Despite multiple anticancer effects, IL2 and IL18 have had limited success as chemotherapeutics because of severe systemic toxicity^{72–74}. Similar to the TNF α -family agents, local production of these cytokines within tumors would limit toxicity while stimulating tumor-infiltration by lymphocytes⁷². Treatment with *Salmonella* expressing LIGHT or CCL21 has been shown to induce leukocyte and neutrophil infiltration and inhibit tumor growth^{20–21}.

Tumor-specific antigens and antibodies

The expression of tumor-specific antigens is another bacterial strategy that utilizes the host immune system (Table 2). It functions by sensitizing immune cells and preventing the

formation of tumors that present those antigens^{22, 60, 81–82}. For example, RAF1 (also known as c-RAF) is a transcription factor upregulated in many tumors²²; prostate-specific antigen (PSA) is upregulated in many prostate tumors⁶⁰; and NY-ESO-1 (also known as CTG1B) is a germ cell protein often expressed by tumor cells⁸². To induce a more efficient immune response, PSA has been fused to cholera toxin subunit B (CtxB), a mucosal adjuvant⁶⁰. Alternately, a non-specific immune response can be induced by the expression of a potent antigen, e.g. canine parvovirus (CPV)⁸¹. To facilitate interaction with immune cells, different protein secretion systems have been employed: for example, RAF1 and CtxB-PSA were fused to the α -hemolysin secretion signal^{22, 60} and CPV was bound to OmpA, a membrane protein that forms outer membrane vesicles⁸¹. Because these strategies rely on a systemic immune response, it is not necessary for these antigens to be expressed in tumors⁸². Also, because the response is retained by the immune system, these bacterial therapies could be used for prevention or as treatment vaccines.

Alternatively, bacteria can be engineered to express single chain antibodies to inhibit proteins necessary for tumor cell function. For example, *C. novyi* has been modified to express single chain antibodies that bind the hypoxia inducible factor 1 α (HIF1 α) antigen⁸³. HIF1 α is an important target because it is associated with resistance to radiotherapy and chemotherapy and poor clinical outcome⁸³. Preliminary studies have shown that bacterially produced antibodies bind the HIF1 α epitope⁸³.

Gene transfer

The ability of therapeutic bacteria to transfer genetic material to mammalian cells was first reported in 1995, when it was shown that *Shigellae* could transfer plasmid DNA into baby hamster kidney cells⁸⁴. Soon after, it was shown that *Salmonella* could also be used for trans-kingdom DNA transfer^{85–86}. These reports generated significant enthusiasm for using bacteria (specifically *Salmonella*) to transfer the genes for cytotoxic and immunological agents into cancer cells (Table 2). Compared to direct expression, this approach has benefits as well as drawbacks. Gene transfer, which utilizes more permanent mammalian systems, may produce stronger, more stable expression. However, expression of the transferred genes may be harder to control⁸⁷; expression could be limited by poor transfer efficiency; transferred genes may be heterogeneously distributed in tissues; and the genes could transfer to tissues other than those they are targeted towards.

Many of the same strategies have been attempted with gene transfer as with direct expression: cytotoxic agents, cytokines and tumor antigens (Table 2). Two early reports describe the transfer of the anti-angiogenic genes, endostatin⁴⁴ and thrombospondin 1⁵¹, which kill tumors by preventing new blood vessel formation and cutting off the nutrient supply⁴⁴. Although direct administration of endostatin to cancer patients showed only minimal antitumor activity, transfer of endostatin from *Salmonella* reduced microvessel density, decreased VEGF expression, and slowed tumor growth in mice⁴⁴. Using a similar strategy as direct expression, reduction of tumor growth was shown by transferring the genes encoding TRAIL and SMAC (also known as DIABLO) into tumor cells from *Salmonella*⁸⁸.

The anti-tumor effects of three cytokines and growth factors have been explored by bacterial gene transfer: IL12^{89–91}, granulocyte/macrophage colony-stimulating factor (GM-CSF)⁹⁰, and Fms-like tyrosine kinase ligand (FLT3L)⁹². Similar to bacterially expressed cytokines, these molecules stimulate NK, T and DC cells^{89–91}. In addition, IL12 induces IFN- γ production and GM-CSF activates neutrophils and macrophages to lyse tumor cells⁹⁰. When expressed together, IL12 and GM-CSF significantly reduce tumor growth in mice, while limiting the systemic toxicity associated with systemic cytokine injection⁹⁰.

The transfer of genes for two tumor antigens has been shown to be effective at reducing tumor growth in mouse models: α -fetoprotein (AFP) and vascular endothelial growth factor receptor 2 (VEGFR2, also known as FLK1)^{93–95}. Antibodies against AFP, an embryonic protein overexpressed in hepatocellular carcinoma and not present in normal adult tissue, prevents formation of liver and colon tumors⁹⁵. VEGFR-2 is an endothelial cell receptor that controls angiogenesis and antibodies against VEGFR2 have been shown to prevent angiogenesis and tumor growth in glioblastoma⁹⁴ and lung cancer⁹³ models.

Gene silencing

A complementary strategy to bacterial induction of gene expression is gene silencing. Silencing is achieved by transferring plasmids encoding small hairpin RNAs (shRNA) from *Salmonella* into cancer cells^{96–97}. Gene-specific shRNAs are processed by the enzyme Dicer into small interfering double-stranded RNAs (siRNAs) that induce the degradation of target mRNAs⁹⁶. To date, two genes have been silenced using this technique, signal transducer and activator of transcription 3 (*Stat3*)⁹⁶ and *Bcl2*⁹⁷. Both factors inhibit apoptosis and STAT3 promotes cancer cell growth; overexpression of these factors has been associated with many tumor types, including prostate cancer and malignant melanoma^{96–97}. Silencing of *Stat3* has been shown to prevent prostate tumor and metastasis formation in mice⁹⁷.

Gene triggering strategies

Control of gene expression is critical for managing the timing and location of drug production. Incorporation of specific promoter sequences upstream of genes that encode anticancer proteins enables control of transcription by external signals. Precise triggering of expression can be used to induce greater intratumoral effects while minimizing systemic toxicity²³. Some gene products require tighter control than others; for example, cytotoxic molecules and cytokines that are known to be toxic cannot be constitutively expressed but tumor-specific antigens do not need to be expressed in tumors and so tight control of the genes expressing these antigens is not necessary⁸².

There are two categories of gene triggering strategies: extracellular triggers and environmental sensors (Table 2). Three external triggers have been investigated: L-arabinose, salicylate and γ -irradiation (Figure 3). The pBAD system utilizes the regulatory protein AraC to respond to extracellular L-arabinose^{17, 28–29} and is very tightly regulated⁹⁸. The salicylate system is also tightly regulated and its cascade amplifies gene expression, producing induction ratios of 20–150 fold *in vitro*⁹⁹. Both L-arabinose and salicylate are suitable and non-toxic biological triggers. In mouse models, it has been shown that intravenous administration of L-arabinose can activate gene expression in colonized tumors²⁹.

The *RecA* mechanism utilizes γ -irradiation as a trigger of gene expression (Figure 3) and is based on the SOS DNA repair system^{23, 26–27, 30}. Irradiation has a major advantage over molecular triggers because it can directly penetrate tumor tissue and is not restricted by diffusion limitations². γ -irradiation causes DNA damage and activates the protein RecA²³, which promotes autoproteolysis of the repressor LexA. The lysis of LexA, a repressor of the *recA* promoter, induces gene expression. This system is amplified by self induction of RecA when LexA is cleaved. To reduce basal expression and increase radiation responsiveness an extra Cheo box has been incorporated into the *recA* promoter, which has been shown to increase expression ten-fold¹⁰⁰.

To date, all environmental triggering strategies have been designed to sense hypoxia using the fumarate and nitrate reduction (FNR) regulator (Figure 3)^{19, 101}. FNR is an oxygen-responsive transcription factor naturally present in *Salmonella*^{19, 101–102}. In the absence of

oxygen, iron-sulfide clusters induce the formation of FNR homodimers that bind to specific DNA sequences and promote transcription^{19, 101}. In the presence of oxygen, the clusters and FNR homodimers disassemble, reducing transcription. Two artificial promoters have been developed that contain FNR-binding sites: FF+20*¹⁹ and hypoxia inducible promoter-1 (HIP1¹⁰¹; Table 2). These two promoters were created by random¹⁹ and directed¹⁰¹ mutagenesis to amplify expression in hypoxia and reduce expression in normoxia¹⁹. To identify bacterial promoters that could be used in environmental triggering strategies, Arrach et al. developed a reporter system that they tested in tumor-bearing mice¹⁰³. The two most active promoters, pflE and ansB, both contained FNR-binding sites and are known to be oxygen dependent¹⁰³. These experiments did, however, identify other promoters that were not oxygen dependent and may rely on alternative environmental triggers.

Detection

Being able to locate colonized bacteria is clinically important because it enables the detection of obscured tumors and metastases. Four different strategies have been implemented to identify bacteria in tumors: bioluminescence, fluorescence, magnetic resonance and positron emission (Table 2). Bioluminescent bacteria are generated by transformation with plasmids containing the luxCDABE operon from *Photobacterium leiognathii*^{5, 17, 104–106}, and fluorescent bacteria are generated by transformation with plasmids containing the gene for green fluorescent protein (GFP)^{5, 31–32}. Both of these mechanisms have proven to be very efficient at identifying tumors in mice using whole mouse imaging^{5, 17, 31–32, 104–106}. These light-based mechanisms may have limited clinical application, however, because of the poor penetration of visible light through tissue.

Alternately, magnetotactic bacteria could be injected and detected by MRI. For example, *Magnetospirillum magneticum* produces magnetite (Fe₃O₄) particles and has been shown to accumulate in tumors³³. For improved tumor targeting, the genes for magnetite production could be transferred into other bacterial strains³³. Two different methods that have been used to detect bacteria with PET are expression of an exogenous viral tyrosine kinase^{34–35} and reliance on endogenous protein kinases³⁶. When herpes simplex thymidine kinase (HSV1-TK) is expressed in *Salmonella*, it selectively phosphorylates and traps the detectable marker 2'-fluoro-1-β-D-arabino-furanosyl-5-iodouracil (FIAU)³⁵. Alternately, the endogenous protein kinases of *E. coli* Nissle 1917 have been shown to phosphorylate and trap [¹⁸F]-2'-Fluoro-2'-deoxy-1-β-D-arabino-furanosyl-5-ethyl-uracil ([¹⁸F]-FEAU)³⁶. Both these methods have successfully been shown to identify bacteria accumulated in mouse tumors^{34–36}.

Conclusions and future perspectives

Recently, many experiments have shown that bacterial therapies can successfully regress tumors and promote survival in mice. However, numerous challenges remain before bacteria can be used in the clinic, including limited drug production, intrinsic bacterial toxicity, targeting efficiency, genetic instability and combination with other therapies. Tuning drug production is necessary to synthesize drugs at high enough concentrations to induce therapeutic effects but not so high that they cause systemic toxicity (see Figure 2). Controlling bacterial toxicity will be critical to ensure safety and permit regulatory approval. Both *Clostridium* and *Salmonella* have been shown to be non-pathogenic in multiple animal species^{46, 65} and in human trials^{54–56, 63}, but any retained virulence could be problematic for immunocompromised late-stage cancer patients. Variable targeting efficiency could lead to poor efficacy for large groups of patients and will affect which sites could be effectively treated with bacteria. Targeting efficacy will also play a large role in the treatment of metastatic disease because, to be effective, bacteria will have to colonize a high percentage

of distal sites. Genetic instability is a potential problem because mutations could create ineffective or harmful phenotypes. The rate of mutation will specify the upper time limit that bacterial colonies could be allowed to remain in tumors. Finally, determining the correct combination of bacteria and other cancer therapies (Tables 1 and 2)^{14, 18, 107–110} will be critical for creating strategies that can completely clear tumors and metastases. Solving these challenges could overcome the limitations that have previously been seen in the clinic^{54–56} (Table 3): reduced toxicity will increase the maximum-tolerated dose; improved targeting will increase tumor colonization; and efficient drug production will promote tumor regression.

All these challenges can be addressed using synthetic biology techniques. Rates of protein drug production can be optimized by manipulating multiple factors¹¹¹, including gene copy number, promoter strength, optimized codons, bacterial metabolism, mRNA secondary structure¹¹² and synthetic ribosome binding sites¹¹³. Both toxicity and targeting are affected by the immune response following injection and innate bacterial virulence. Determining which virulence factors are essential for targeting and which introduce unnecessary toxicity can be achieved by screening knockouts of the pathogenicity genes that, for example, enable evasion of the immune system, induce uptake into cells, promote intracellular replication and stimulate cytokine synthesis¹¹⁴. Other targeting mechanisms can be enhanced by genetic manipulation of endogenous chemoreceptors¹⁶, selective control of bacterial proliferation in tumors, and strategies to avoid sequestration by neutrophils. Similarly, genetic stability could be enhanced by incorporating engineered genes on the bacterial chromosome and limiting homologous recombination and horizontal gene transfer.

This moment in history is a turning point for bacterial therapies. The preliminary proof-of-concept experiments have demonstrated the vast capacity of bacteria for treating cancer and illustrated the large number of effective tools that these robot factories possess. The ultimate bacterial therapy will consist of a collection of strains designed for specialized purposes rather than a single perfect strain. Successful treatment could utilize these strains cooperatively and in combination with molecular chemotherapy: a detectable facultative anaerobe could be used for diagnosis; an engineered immunogenic stain could be used to sensitize the immune system; an obligate anaerobe could be used to treat inoperable primary tumors; and a motile *Salmonella* strain that controllably produces a cytotoxic agent could be used to treat diffuse tumors and metastatic disease. All bacterial therapies will be in used in combination with other therapeutics (Tables 1 and 2)^{14, 18, 107–110}, which will have a synergistic effect: small molecules would kill cancer cells close to blood vessels and bacteria would kill cells far from vessels (Figure 2). The greatest strength of bacterial therapies is their genetic flexibility, which enables tuning for individualized therapy, targeting to multiple tumor sites and precise control of cytotoxicity. Once perfected, anticancer bacteria are expected to be an essential clinical tool, which can perform functions unachievable by other therapies, and can detect, prevent, and treat tumors and metastases.

Acknowledgments

This work was partly supported by the US National Institutes of Health, National Cancer Institute grant CA120825.

References

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. *Nat Rev Cancer*. 2006; 6:583–592. [PubMed: 16862189]
2. St Jean AT, Zhang MM, Forbes NS. Bacterial therapies: completing the cancer treatment toolbox. *Current Opinion in Biotechnology*. 2008; 19:511–517. [PubMed: 18760353]

3. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. *Nat Med.* 1998; 4:655–657. [PubMed: 9623964]
4. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. *Cancer Res.* 1997; 57:4537–4544. [PubMed: 9377566]
5. Yu YA, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. *Nat Biotechnol.* 2004; 22:313–320. [PubMed: 14990953]
6. Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect of histolytic infection and toxin on transplantable mouse tumors. *Proc Soc Exp Biol Med.* 1947; 66:461–467. [PubMed: 18921791]
7. Malmgren RA, Flanigan CC. Localization of the vegetative form of *Clostridium tetani* in mouse tumor following intravenous spore administration. *Cancer Res.* 1955; 15:473–478. [PubMed: 13240693]
8. Kohwi Y, Imai K, Tamura Z, Hashimoto Y. Antitumor effect of *Bifidobacterium infantis* in mice. *Gann.* 1978; 69:613–618. [PubMed: 729960]
9. Bhatnagar PK, Awasthi A, Nomellini JF, Smit J, Suresh MR. Anti-tumor effects of the bacterium *Caulobacter crescentus* in murine tumor models. *Cancer Biology & Therapy.* 2006; 5:485–491. [PubMed: 16582592]
10. Pan ZK, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant *Listeria monocytogenes* vaccine. *Cancer Research.* 1999; 59:5264–5269. [PubMed: 10537307]
11. Kim SH, Castro F, Paterson Y, Gravekamp C. High Efficacy of a *Listeria*-Based Vaccine against Metastatic Breast Cancer Reveals a Dual Mode of Action. *Cancer Research.* 2009; 69:5860–5866. [PubMed: 19584282]
12. Arakawa M, Sugiura K, Reilly HC, Stock CC. Oncolytic effect of *Proteus mirabilis* upon tumor-bearing animals. 2. Effect on transplantable mouse and rat tumors. *Gann.* 1968; 59:117. [PubMed: 5723056]
13. Maletzki C, Linnebacher M, Kreikemeyer B, Emmrich J. Pancreatic cancer regression by intratumoural injection of live *Streptococcus pyogenes* in a syngeneic mouse model. *Gut.* 2008; 57:483–491. [PubMed: 18025068]
14. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. *Proc Natl Acad Sci U S A.* 2001; 98:15155–15160. [PubMed: 11724950]
15. Kasinskas RW, Forbes NS. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. *Biotechnology and Bioengineering.* 2006; 94:710–721. [PubMed: 16470601]
16. Kasinskas RW, Forbes NS. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. *Cancer Research.* 2007; 67:3201–3209. [PubMed: 17409428]
17. Nguyen VH, et al. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. *Cancer Res.* 2010; 70:18–23. [PubMed: 20028866]
18. Jiang SN, et al. Inhibition of Tumor Growth and Metastasis by a Combination of Escherichia coli-mediated Cytolytic Therapy and Radiotherapy. *Mol Ther.* 2010
19. Ryan RM, et al. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. *Gene Ther.* 2009; 16:329–339. [PubMed: 19177133]
20. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104:12879–12883. [PubMed: 17652173]
21. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. *Cancer Immunology Immunotherapy.* 2009; 58:769–775. [PubMed: 18633610]
22. Gentshev I, et al. Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. *BMC Cancer.* 2005; 5:15. [PubMed: 15703070]

23. Ganai S, Arenas RB, Forbes NS. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. *Br J Cancer*. 2009; 101:1683–1691. [PubMed: 19861961]
24. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Inhibition of tumor growth using salmonella expressing Fas ligand. *J Natl Cancer Inst*. 2008; 100:1113–1116. [PubMed: 18664657]
25. Theys J, et al. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha. *Applied and Environmental Microbiology*. 1999; 65:4295–4300. [PubMed: 10508051]
26. Nuyts S, et al. Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. *Anticancer Res*. 2001; 21:857–861. [PubMed: 11396175]
27. Nuyts S, et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. *Gene Ther*. 2001; 8:1197–1201. [PubMed: 11509951]
28. Loessner H, et al. Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. *Cell Microbiol*. 2007; 9:1529–1537. [PubMed: 17298393]
29. Stritzker J, et al. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. *Int J Med Microbiol*. 2007; 297:151–1562. [PubMed: 17448724]
30. Nuyts S, et al. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. *Radiat Res*. 2001; 155:716–723. [PubMed: 11302769]
31. Zhao M, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. *Proc Natl Acad Sci U S A*. 2005; 102:755–760. [PubMed: 15644448]
32. Hoffman RM, Zhao M. Whole-body imaging of bacterial infection and antibiotic response. *Nature Protocols*. 2006; 1:2988–2994.
33. Benoit MR, et al. Visualizing Implanted Tumors in Mice with Magnetic Resonance Imaging Using Magnetotactic Bacteria. *Clinical Cancer Research*. 2009; 15:5170–5177. [PubMed: 19671860]
34. Tjuvajev J, et al. Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET (TM)) for diagnostic imaging. *Journal of Controlled Release*. 2001; 74:313–315. [PubMed: 11489512]
35. Soghomonyan SA, et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. *Cancer Gene Therapy*. 2005; 12:101–108. [PubMed: 15499377]
36. Brader P, et al. Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. *Clinical Cancer Research*. 2008; 14:2295–2302. [PubMed: 18369089]
37. Nagakura C, et al. Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. *Anticancer Res*. 2009; 29:1873–1878. [PubMed: 19528442]
38. Lambin P, et al. Colonisation of *Clostridium* in the body is restricted to hypoxic and necrotic areas of tumours. *Anaerobe*. 1998; 4:183–188. [PubMed: 16887640]
39. Minton NP. Clostridia in cancer therapy. *Nature Reviews Microbiology*. 2003; 1:237–242.
40. Forbes NS, Munn LL, Fukumura D, Jain RK. Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. *Cancer Research*. 2003; 63:5188–5193. [PubMed: 14500342]
41. Leschner S, et al. Tumor Invasion of Salmonella enterica Serovar Typhimurium Is Accompanied by Strong Hemorrhage Promoted by TNF-alpha. *Plos One*. 2009; 4
42. Sznol M, Lin SL, Bermudes D, Zheng LM, King I. Use of preferentially replicating bacteria for the treatment of cancer. *J Clin Invest*. 2000; 105:1027–1030. [PubMed: 10772643]
43. Clairmont C, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. *J Infect Dis*. 2000; 181:1996–2002. [PubMed: 10837181]


44. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by *Salmonella choleraesuis* in murine tumor models. *Journal of Gene Medicine*. 2004; 6:1382–1393. [PubMed: 15468191]
45. Zheng LM, et al. Tumor amplified protein expression therapy: *Salmonella* as a tumor-selective protein delivery vector. *Oncology Research*. 2000; 12:127–135. [PubMed: 11216671]
46. Low KB, et al. Lipid A mutant *Salmonella* with suppressed virulence and TNF α induction retain tumor-targeting in vivo. *Nat Biotechnol*. 1999; 17:37–41. [PubMed: 9920266]
47. Theys J, et al. Repeated cycles of *Clostridium*-directed enzyme prodrug therapy result in sustained antitumor effects in vivo. *Br J Cancer*. 2006; 95:1212–1219. [PubMed: 17024128]
48. Zhao M, et al. Targeted therapy with a *Salmonella typhimurium* leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. *Cancer Research*. 2006; 66:7647–7652. [PubMed: 16885365]
49. Streilein JW. Unraveling immune privilege. *Science*. 1995; 270:1158–1159. [PubMed: 7502038]
50. Westphal K, Leschner S, Jablonska J, Loessner H, Weiss S. Containment of tumor-colonizing bacteria by host neutrophils. *Cancer Research*. 2008; 68:2952–2960. [PubMed: 18413765]
51. Lee CH, Wu CL, Shiau AL. Systemic administration of attenuated *Salmonella choleraesuis* carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. *Cancer Gene Therapy*. 2005; 12:175–184. [PubMed: 15375381]
52. Lee CH, Wu CL, Tai YS, Shiau AL. Systemic administration of attenuated *Salmonella choleraesuis* in combination with cisplatin for cancer therapy. *Molecular Therapy*. 2005; 11:707–716. [PubMed: 15851009]
53. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. *Cancer Res*. 1989; 49:6449–6465. [PubMed: 2684393]
54. Heimann DM, Rosenberg SA. Continuous intravenous administration of live genetically modified *salmonella typhimurium* in patients with metastatic melanoma. *J Immunother*. 2003; 26:179–180. [PubMed: 12616110]
55. Toso JF, et al. Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma. *Journal of Clinical Oncology*. 2002; 20:142–152. [PubMed: 11773163]
56. Nemunaitis J, et al. Pilot trial of genetically modified, attenuated *Salmonella* expressing the *E. coli* cytosine deaminase gene in refractory cancer patients. *Cancer Gene Ther*. 2003; 10:737–744. [PubMed: 14502226]
57. Hall, SS. *A commotion in the blood : life, death, and the immune system*. New York: Henry Holt; 1997.
58. Coley WB. Contribution to the knowledge of sarcoma. *Ann. Surgery*. 1891; 14:199–220.
59. Nauts HC, Swift WE, Coley BL. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light of modern research. *Cancer Research*. 1946; 6:205–216. [PubMed: 21018724]
60. Fensterle J, et al. Cancer immunotherapy based on recombinant *Salmonella enterica* serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. *Cancer Gene Ther*. 2008; 15:85–93. [PubMed: 18084243]
61. Mottram JC. Factors of importance in radiosensitivity of tumors. *Br J Radiol*. 1936; 9:606–614.
62. Möse JR, Möse G. Oncogenesis by clostridia. I. Activity of *Clostridium butyricum* (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. *Cancer Res*. 1964; 24:212–216. [PubMed: 14115686]
63. Carey RW, Holland JF, Whang HY, Neter E, Bryant B. Clostridial oncolysis in man. *Europ J Cancer*. 1967; 3:37–46.
64. Lee CH, Wu CL, Shiau AL. *Salmonella choleraesuis* as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. *International Journal of Cancer*. 2008; 122:930–935.
65. Thamm DH, et al. Systemic administration of an attenuated, tumor-targeting *Salmonella typhimurium* to dogs with spontaneous neoplasia: Phase I evaluation. *Clinical Cancer Research*. 2005; 11:4827–4834. [PubMed: 16000580]

66. Jia LJ, et al. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. *Cancer Science*. 2007; 98:1107–1112. [PubMed: 17498202]
67. Chen G, et al. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity. *Cancer Science*. 2009; 100:2437–2443. [PubMed: 19793349]
68. Bermudes D, Low B, Pawelek J. *Cancer Gene Therapy*. 2000;57–63.
69. Hedley D, Ogilvie L, Springer C. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. *Nat Rev Cancer*. 2007; 7:870–879. [PubMed: 17943135]
70. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. *Nature Reviews Cancer*. 2004; 4:437–447.
71. Walczak H, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *Nat Med*. 1999; 5:157–163. [PubMed: 9930862]
72. Barbe S, et al. Secretory production of biologically active rat interleukin-2 by *Clostridium acetobutylicum* DSM792 as a tool for anti-tumor treatment. *FEMS Microbiol Lett*. 2005; 246:67–73. [PubMed: 15869963]
73. Saltzman DA, et al. Attenuated *Salmonella typhimurium* containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. *Cancer Biother Radiopharm*. 1996; 11:145–153. [PubMed: 10851531]
74. Loeffler M, Le'Negrata G, Krajewska M, Reed JC. IL-18-producing *Salmonella* inhibit tumor growth. *Cancer Gene Therapy*. 2008; 15:787–794. [PubMed: 18654612]
75. Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA. Attenuated *Salmonella typhimurium* with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. *J Pediatr Surg*. 2008; 43:1153–1158. [PubMed: 18558199]
76. Sorenson BS, Banton KL, Frykman NL, Leonard AS, Saltzman DA. Attenuated *Salmonella typhimurium* with IL-2 gene reduces pulmonary metastases in murine osteosarcoma. *Clin Orthop Relat Res*. 2008; 466:1285–1291. [PubMed: 18421536]
77. Al-Ramadi BK, et al. Potent anti-tumor activity of systemically-administered IL-2-expressing *Salmonella* correlates with decreased angiogenesis and enhanced tumor apoptosis. *Clinical Immunology*. 2009; 130:89–97. [PubMed: 18849195]
78. Barnett SJ, et al. Attenuated *Salmonella typhimurium* invades and decreases tumor burden in neuroblastoma. *J Pediatr Surg*. 2005; 40:993–997. discussion 997–8. [PubMed: 15991184]
79. Feltis BA, et al. Liver and circulating NK1.1(+)/CD3(-) cells are increased in infection with attenuated *Salmonella typhimurium* and are associated with reduced tumor in murine liver cancer. *Journal of Surgical Research*. 2002; 107:101–107. [PubMed: 12384070]
80. Saltzman DA. Antitumor mechanisms of attenuated *Salmonella typhimurium* containing the gene for human interleukin-2: a novel antitumor agent? *J Pediatr Surg*. 1997; 32:301–306. [PubMed: 9044141]
81. Lee SR, et al. Multi-Immunogenic Outer Membrane Vesicles Derived from a MsbB-Deficient *Salmonella enterica* Serovar Typhimurium Mutant. *Journal of Microbiology and Biotechnology*. 2009; 19:1271–1279. [PubMed: 19884791]
82. Nishikawa H, et al. In vivo antigen delivery by a *Salmonella typhimurium* type III secretion system for therapeutic cancer vaccines. *J Clin Invest*. 2006; 116:1946–1954. [PubMed: 16794737]
83. Groot AJ, et al. Functional antibodies produced by oncolytic clostridia. *Biochemical and Biophysical Research Communications*. 2007; 364:985–989. [PubMed: 17971292]
84. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated *Shigella* as a DNA delivery vehicle for DNA-mediated immunization. *Science*. 1995; 270:299–302. [PubMed: 7569980]
85. Darji A, et al. Oral somatic transgene vaccination using attenuated *S. typhimurium*. *Cell*. 1997; 91:765–775. [PubMed: 9413986]
86. Weiss S, Chakraborty T. Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers. *Curr Opin Biotechnol*. 2001; 12:467–472. [PubMed: 11604322]
87. Palffy R, et al. Bacteria in gene therapy: bacteriofection versus alternative gene therapy. *Gene Ther*. 2006; 13:101–105. [PubMed: 16163379]

88. Fu W, Chu L, Han XW, Liu XY, Ren DM. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated *Salmonella enterica* Serovar Typhimurium in murine tumor models. *Journal of Gene Medicine*. 2008; 10:690–701. [PubMed: 18338832]
89. Li YH, et al. Prophylaxis of tumor through oral administration of IL-12 GM-CSF gene carried by live attenuated salmonella. *Chinese Science Bulletin*. 2001; 46:1107–1112.
90. Li YH, et al. Oral cytokine gene therapy against murine tumor using attenuated *Salmonella typhimurium*. *International Journal of Cancer*. 2001; 94:438–443.
91. Qi H, Li YH, Zheng SB. [Oral gene therapy via live attenuated *Salmonella* leads to tumor regression and survival prolongation in mice]. *Nan Fang Yi Ke Da Xue Xue Bao*. 2006; 26:1738–1741. [PubMed: 17259109]
92. Yoon WS, Choi WC, Sin JI, Park YK. Antitumor therapeutic effects of *Salmonella typhimurium* containing Flt3 Ligand expression plasmids in melanoma-bearing mouse. *Biotechnology Letters*. 2007; 29:511–516. [PubMed: 17235489]
93. Zuo SG, et al. Orally administered DNA vaccine delivery by attenuated *Salmonella typhimurium* targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. *Biol Pharm Bull*. 2010; 33:174–182. [PubMed: 20118536]
94. Feng K, et al. Anti-angiogenesis effect on glioma of attenuated *Salmonella typhimurium* vaccine strain with flk-1 gene. *J Huazhong Univ Sci Technolog Med Sci*. 2004; 24:389–391. [PubMed: 15587406]
95. Chou CK, Hung JY, Liu JC, Chen CT, Hung MC. An attenuated *Salmonella* oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein. *Cancer Gene Therapy*. 2006; 13:746–752. [PubMed: 16410824]
96. Zhang L, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated *Salmonella enterica* serovar typhimurium carrying plasmid-based small interfering RNAs. *Cancer Research*. 2007; 67:5859–5864. [PubMed: 17575154]
97. Yang N, Zhu X, Chen L, Li S, Ren D. Oral administration of attenuated *S. typhimurium* carrying shRNA-expressing vectors as a cancer therapeutic. *Cancer Biol Ther*. 2008; 7:145–151. [PubMed: 18059172]
98. Guzman LM, Belin D, Carson MJ, Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol*. 1995; 177:4121–4130. [PubMed: 7608087]
99. Royo JL, et al. In vivo gene regulation in *Salmonella* spp. by a salicylate-dependent control circuit. *Nature Methods*. 2007; 4:937–942. [PubMed: 17922017]
100. Nuyts S, et al. Insertion or deletion of the Cheo box modifies radiation inducibility of *Clostridium* promoters. *Appl Environ Microbiol*. 2001; 67:4464–4470. [PubMed: 11571144]
101. Mengesha A, et al. Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated *Salmonella*. *Cancer Biology & Therapy*. 2006; 5:1120–1128. [PubMed: 16855381]
102. Strauch KL, Lenk JB, Gamble BL, Miller CG. Oxygen regulation in *Salmonella typhimurium*. *J Bacteriol*. 1985; 161:673–680. [PubMed: 3918022]
103. Arrach N, Zhao M, Porwollik S, Hoffman RM, McClelland M. *Salmonella* promoters preferentially activated inside tumors. *Cancer Res*. 2008; 68:4827–4832. [PubMed: 18559530]
104. Min JJ, et al. Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting *Escherichia coli*. *Molecular Imaging and Biology*. 2008; 10:54–61. [PubMed: 17994265]
105. Min JJ, Nguyen VH, Kim HJ, Hong YJ, Choy HE. Quantitative bioluminescence imaging of tumor-targeting bacteria in living animals. *Nat Protoc*. 2008; 3:629–636. [PubMed: 18388945]
106. Cheng CM, et al. Tumor-targeting prodrug-activating bacteria for cancer therapy. *Cancer Gene Therapy*. 2008; 15:393–401. [PubMed: 18369382]
107. Gericke D, Engelbart K. Oncolysis by *Clostridia* .2. Experiments on tumor spectrum with variety of *Clostridia* in combination with heavy metal. *Cancer Research*. 1964; 24:217. [PubMed: 14115687]

108. Dang LH, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. *Cancer Biology & Therapy*. 2004; 3:326–337. [PubMed: 14739784]
109. Bettegowda C, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100:15083–15088. [PubMed: 14657371]
110. Cheong I, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. *Science*. 2006; 314:1308–1311. [PubMed: 17124324]
111. Voigt CA. Genetic parts to program bacteria. *Curr Opin Biotechnol*. 2006; 17:548–557. [PubMed: 16978856]
112. Pfleger BF, Pitera DJ, Smolke CD, Keasling JD. Combinatorial engineering of intergenic regions in operons tunes expression of multiple genes. *Nat Biotechnol*. 2006; 24:1027–1032. [PubMed: 16845378]
113. Salis HM, Mirsky EA, Voigt CA. Automated design of synthetic ribosome binding sites to control protein expression. *Nat Biotechnol*. 2009; 27:946–950. [PubMed: 19801975]
114. Ohl ME, Miller SI. Salmonella: a model for bacterial pathogenesis. *Annu Rev Med*. 2001; 52:259–274. [PubMed: 11160778]
115. Engelbart K, Gericke D. Oncolysis by Clostridia .V. Transplanted tumors of hamster. *Cancer Research*. 1964; 24:239. [PubMed: 14115690]
116. Thiele EH, Boxer GE, Arison RN. Oncolysis by Clostridia .3. Effects of Clostridia + chemotherapeutic agents on rodent tumors. *Cancer Research*. 1964; 24:222. [PubMed: 14115688]
117. Mohr U, Bolding WH, Behagel HA, Emminger A. Oncolysis by a new strain of Clostridium. *Cancer Research*. 1972; 32:1122. [PubMed: 5030812]
118. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. *Cellular Microbiology*. 2008; 10:1235–1248. [PubMed: 18208564]
119. Luo X, et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. *Oncol Res*. 2001; 12:501–508. [PubMed: 11939414]
120. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. *Journal of Immunotherapy*. 2002; 25:218–225. [PubMed: 12000863]
121. Zhao M, et al. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. *Proc Natl Acad Sci U S A*. 2007; 104:10170–10174. [PubMed: 17548809]
122. Kimura H, et al. Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. *Cell Prolif*. 2010; 43:41–48. [PubMed: 19922490]
123. Jia LJ, et al. Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. *Cancer Biol Ther*. 2005; 4:840–845. [PubMed: 16210914]
124. Platt J, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. *European Journal of Cancer*. 2000; 36:2397–2402. [PubMed: 11094316]
125. Shilling DA, et al. Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. *Clin Exp Immunol*. 2007; 149:109–116. [PubMed: 17459080]
126. Al-Ramadi BK, et al. Attenuated bacteria as effectors in cancer immunotherapy. *Ann N Y Acad Sci*. 2008; 1138:351–357. [PubMed: 18837910]
127. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. *Gene Therapy*. 2002; 9:291–296. [PubMed: 11896468]
128. Liu SC, et al. Optimized Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. *Cancer Research*. 2008; 68:7995–8003. [PubMed: 18829557]
129. Dubois L, et al. Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression. *Br J Cancer*. 2007; 96:758–761. [PubMed: 17311022]


130. Jazowiecka-Rakus J, Szala S. Antitumour activity of *Salmonella typhimurium* VNP20047 in B16(F10) murine melanoma model. *Acta Biochimica Polonica*. 2004; 51:851–856. [PubMed: 15448746]
131. Friedlos F, et al. Attenuated *Salmonella* targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. *Clinical Cancer Research*. 2008; 14:4259–4266. [PubMed: 18594008]
132. Fu W, et al. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via *Salmonella* against murine tumors. *Cancer Gene Therapy*. 2008; 15:474–484. [PubMed: 18437183]
133. Fu W, Lan HK, Liang SH, Gao T, Ren DM. Suicide gene/prodrug therapy using salmonella-mediated delivery of *Escherichia coli* purine nucleoside phosphorylase gene and 6-methoxypurine 2'-deoxyriboside in murine mammary carcinoma 4T1 model. *Cancer Science*. 2008; 99:1172–1179. [PubMed: 18429958]
134. Mei S, Theys J, Landuyt W, Anne J, Lambin P. Optimization of tumor-targeted gene delivery by engineered attenuated *Salmonella typhimurium*. *Anticancer Res*. 2002; 22:3261–3266. [PubMed: 12530073]
135. Hayashi K, et al. Cancer metastasis directly eradicated by targeted therapy with a modified *Salmonella typhimurium*. *J Cell Biochem*. 2009; 106:992–998. [PubMed: 19199339]
136. Hayashi K, et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*. *Cell Cycle*. 2009; 8:870–875. [PubMed: 19221501]
137. Dresselaers T, et al. Non-invasive ¹⁹F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant *Salmonella* in tumours. *Br J Cancer*. 2003; 89:1796–1801. [PubMed: 14583786]
138. Heppner F, Mose JR. The liquefaction (oncolysis) of malignant gliomas by a non pathogenic *Clostridium*. *Acta Neurochir (Wien)*. 1978; 42:123–125. [PubMed: 696441]



Nature Reviews | Cancer

Figure 1. Bacteria are the optimal *robot factory* cancer therapies


A) The perfect cancer therapy would be able to perform six important functions: target tumors, produce cytotoxic molecules, self-propel, respond to triggering signals, sense the local environment and produce externally detectable signals. *B*) Bacteria have biological mechanisms to perform these functions: gene translation machinery to produce anticancer proteins (green); flagella to chemotax; specific gene promoter regions to respond to molecular signals (purple cubes); chemotaxis receptors (orange); and 5) machinery to produce detectable molecules (red). *C*) The number of papers describing bacterial anti-cancer therapies has grown exponentially (black line) since the mid-1990s.



Nature Reviews | Cancer

Figure 2. The transport properties of bacterial therapies produce preferable drug concentration profiles

When injected systemically, bacteria (red syringe, green organisms), specifically accumulate in tumors and migrate to distal regions far from vasculature (brown cells). These distal regions are typically hypoxic and hypoglycemic and contain quiescent and necrotic cells. Once triggered (small red arrows), bacteria begin to produce therapeutic molecules (red ovoids) that diffuse (large red arrows) into viable tissue (clear cells). Systemically injected (small blue arrows), passive chemotherapeutic molecules (blue cubes) diffuse into tumor tissue from blood vessels (large blue arrows). The concentration of bacterially produced molecules (red lines) is greatest in distal tumor regions and would remain constant as long as expression of these proteins continues. The concentration of chemotherapeutic molecules is greatest in systemic blood and drops as it is cleared by the liver or kidneys. Based on these profiles, bacterially produced molecules will be more cytotoxic (dotted line) in the distal regions of tumors and less systemically toxic. The profile of passive molecules is less favorable, with more systemic toxicity and less efficacy deep in tissue.



Nature Reviews | Cancer

Figure 3. Gene triggering systems

A) The *pBAD* system, which responds to extracellular l-arabinose, contains two components: the arabinose sensitive protein AraC and the *pBAD* promoter. Constitutively expressed regulator AraC induces transcription by binding to the *pBAD* promoter. AraC is a positive and negative regulator of *pBAD*: it activates transcription in the presence of arabinose and represses transcription in its absence. **B)** The salicylate cascade system utilized a two salicylate-sensitive regulator proteins, nahR and xylS2 to maintain tight regulation. In the presence of salicylate, nahR activates transcription from the promoter *Psal*, leading to the expression of XylS2. XylS2, which is also sensitive to salicylate, activates transcription from the promoter *Pm*. **C)** The *RecA* system senses γ -irradiation, which causes DNA damage. This damage activates RecA, which induces autoproteolysis of LexA. Transcription is induced when LexA, a repressor of the *recA* promoter, releases from DNA. Feed-forward regulation increases the RecA concentration when the system is active. **D)** The FNR system turns on in hypoxic environments. The absence of oxygen promotes dimerization of FNR, which induces transcription. Multiple promoters bind FNR, including FF+20*, HIP-1, pflE and ansB.

Table 1

Efficacy of bacterial therapies and strategies in animal models

<u>A. Strategies showing tumor regression and/or increased survival</u>	
Native bacterial toxicity	
<i>Bifidobacterium</i>	8
<i>Caulobacter</i>	9
<i>Clostridium</i>	6, 62, 115–117
<i>Escherichia</i>	118
<i>Listeria</i>	10–11
<i>Proteus</i>	12
<i>Salmonella</i>	4, 37, 46, 48, 64–67, 119–122
<i>Streptococcus</i>	13
Combination with other therapies	
<i>Clostridium</i>	14, 107–110
<i>Escherichia</i>	18
<i>Salmonella</i>	52, 123–125
Agents with control of expression	
<i>Salmonella</i>	19, 23
Expression of Anticancer Agents	
<i>Escherichia</i>	18
<i>Salmonella</i>	20–22, 24, 74–79, 81–82, 126
Gene Transfer	
<i>Salmonella</i>	44, 51, 88–95
RNAi	
<i>Salmonella</i>	96
Prodrug cleavage	
<i>Clostridium</i>	47, 127–129
<i>Salmonella</i>	130–134
<u>B. Strategies that reduced metastatic burden or prevented metastasis formation</u>	
Native bacterial toxicity	
<i>Salmonella</i>	121, 135–136
Expression of Anticancer Agents	
<i>Escherichia</i>	18
<i>Salmonella</i>	20–21, 24, 74–76, 93
<u>C. Sites targeted showing either tumor regression or increased survival</u>	
Breast cancer	48, 131
Colon cancer	131
Hepatocellular carcinoma	64
Melanoma	130–131
Neuroblastoma	78
Pancreatic cancer	13, 37
Prostate cancer	96

Spinal cord glioma

122

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 2

Bacterial strategies

A. Expressed anticancer agents*Cytotoxic agents*

Cytolysin A (ClyA, HlyE)	17–19
Fas Ligand	24
TNF α	25–27
TRAIL	23

Cytokines

CCL21	21
Interleukin 2 (IL-2)	72–73, 75–80
Interleukin 18 (IL-18)	74
LIGHT	20

Antigens and antibodies

C-Raf	22
CtxB-PSA fusion protein	60
CPV-OmpA fusion protein	81
NY-ESO-1 tumor antigen	82
Single chain HIF-1 α antibodies	83

B. Genetic transfer*Cytotoxic and antiangiogenic agents*

Endostatin	44
Thrombospondin-1	51
TRAIL and Smac	88

Cytokines and growth factors

Interleukin 12 (IL-12)	89–91
GM-CSF	90
Flt3 Ligand	92

Tumor antigens

α -fetoprotein (AFP)	95
Flk-1	93–94

Gene silencing (shRNA)

Stat3	96
Bcl2	97

C. Gene triggering strategies

<i>Signal</i>	<i>Promoter</i>	
γ -irradiation	pRecA	23, 26–27, 30
L-arabinose	pBAD	17, 28–29
Oxygen (FNR)	FF+20*	19
	HIP-1	101
	pflE and ansB	103
Salicylate	XylS2-dependent <i>Pm</i> promoter	99

D. Combinations with other treatments

Anti-vascular agents	14, 123
Chemotherapeutic drugs	14, 51, 108, 110
Heat shock proteins	125
Heavy metals	107
Radiation	18, 109, 124

E. Imaging strategies

Bioluminescence	5, 17, 104–106
Fluorescence	5, 31–32
Magnetic resonance (MRI)	33, 137
Positron Emission (PET)	34–36

Table 3

Published human trials using bacterial cancer therapies

Strain	Cancer type	n	Responses	Ref.
<i>C. butyricum</i> M-55	Squamous cell carcinoma, metastatic, malignant neuroma, leiomyosarcoma, melanoma, sinus carcinoma	5	Oncolysis (3)	63
<i>C. butyricum</i> M-55	Vascular glioblastoma	49	Oncolysis	138
<i>S. typhimurium</i> VNP20009	Metastatic melanoma and renal cell carcinoma	25	Focal tumor colonization (3)	55
<i>S. typhimurium</i> VNP20009	Metastatic melanoma	4	Tumor biopsy culture positive for VNP20009 (1)	54
<i>S. typhimurium</i> VNP20009 TAPET-CD	Squamous cell carcinoma, adenocarcinoma	3	Intratumoral bacterial colonization (2)	56